ArticleTherapeutic advances in medical oncology2013
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.
Article in Therapeutic advances in medical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome.Cancer immunology, immunotherapy : CII · 2014Trial
- Article
- Hypericin-loaded in modified theranostic liposome nanoplatform: a preliminary in vivo study of targeting and diagnosis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Differential Expression of Autophagy-Related Long Non-Coding RNA in Melanoma.Bulletin of experimental biology and medicine · 2023Article
- Piperine-Chlorogenic Acid Hybrid Inhibits the Proliferation of the SK-MEL-147 Melanoma Cells by Modulating Mitotic Kinases.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Ornidazole suppresses CD133+ melanoma stem cells via inhibiting hedgehog signaling pathway and inducing multiple death pathways in a mouse model.Croatian medical journal · 2022Article
- A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma.Cancer science · 2022Article
- A novel chalcone derivative has antitumor activity in melanoma by inducing DNA damage through the upregulation of ROS products.Cancer cell international · 2020Article
- Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma.NPJ systems biology and applications · 2018Article
- Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.Hormones & cancer · 2017Article
- FAK regulates E-cadherin expression via p-SrcY416/p-ERK1/2/p-Stat3Y705 and PPARγ/miR-125b/Stat3 signaling pathway in B16F10 melanoma cells.Oncotarget · 2017Article
- Burden of illness for metastatic melanoma in Canada, 2011-2013.Current oncology (Toronto, Ont.) · 2016Article
- Immune based therapy for melanoma.The Indian journal of medical research · 2016Review
- Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results.OncoTargets and therapy · 2016Article
- Article
- Metastatic breast disease from cutaneous malignant melanoma.International journal of surgery case reports · 2014Article
- Evaluating biomarkers in melanoma.Frontiers in oncology · 2014Review
- Malignant Melanoma.Healthcare (Basel, Switzerland) · 2013Review
- Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts.Journal of experimental & clinical cancer research : CR · 2013Article
- Melanoma biomolecules: independently identified but functionally intertwined.Frontiers in oncology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic melanoma is one of the most challenging malignancies to treat and often has a poor outcome. Until recently, systemic treatment options were limited, with poor response rates and no survival advantage. However, the treatment of metastatic melanoma has been revolutionized by developments in targeted therapy and immunotherapy; the BRAF inhibitor, vemurafenib, and anticytotoxic T-lymphocyte antigen 4 antibody, ipilimumab, are the first agents to demonstrate a survival benefit. Despite the success of these treatments, most patients eventually progress, and research into response and resistance mechanisms, rationally designed combination therapies and evaluation of the role of these agents in the adjuvant setting is critically important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.